SG11202007117RA - 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof - Google Patents
4-methyldihydropyrimidinone compounds and pharmaceutical use thereofInfo
- Publication number
- SG11202007117RA SG11202007117RA SG11202007117RA SG11202007117RA SG11202007117RA SG 11202007117R A SG11202007117R A SG 11202007117RA SG 11202007117R A SG11202007117R A SG 11202007117RA SG 11202007117R A SG11202007117R A SG 11202007117RA SG 11202007117R A SG11202007117R A SG 11202007117RA
- Authority
- SG
- Singapore
- Prior art keywords
- methyldihydropyrimidinone
- compounds
- pharmaceutical use
- pharmaceutical
- methyldihydropyrimidinone compounds
- Prior art date
Links
- OTKGWSNZPZFOIU-UHFFFAOYSA-N 4-methyl-3,4-dihydro-1h-pyrimidin-2-one Chemical class CC1NC(=O)NC=C1 OTKGWSNZPZFOIU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018035597 | 2018-02-28 | ||
| PCT/JP2019/007433 WO2019167981A1 (en) | 2018-02-28 | 2019-02-27 | 4-methyldihydropyrimidinone compound and medicinal use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007117RA true SG11202007117RA (en) | 2020-08-28 |
Family
ID=67805061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007117RA SG11202007117RA (en) | 2018-02-28 | 2019-02-27 | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10899717B2 (en) |
| EP (1) | EP3760616A4 (en) |
| JP (1) | JP7282546B2 (en) |
| KR (1) | KR20200126973A (en) |
| CN (1) | CN111741947B (en) |
| AR (1) | AR114270A1 (en) |
| AU (1) | AU2019228915A1 (en) |
| BR (1) | BR112020016785A2 (en) |
| CA (1) | CA3087994A1 (en) |
| CL (1) | CL2020002187A1 (en) |
| CO (1) | CO2020011860A2 (en) |
| IL (1) | IL276323A (en) |
| MX (1) | MX2020008982A (en) |
| PE (1) | PE20210550A1 (en) |
| PH (1) | PH12020551341A1 (en) |
| RU (1) | RU2020131402A (en) |
| SG (1) | SG11202007117RA (en) |
| TW (1) | TW202000650A (en) |
| WO (1) | WO2019167981A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| AU2019227250B2 (en) | 2018-02-28 | 2021-11-04 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
| WO2021149786A1 (en) | 2020-01-24 | 2021-07-29 | Japan Tobacco Inc. | Methods of treating cancer using dihydropyrimidin-2-one compounds |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485107A (en) | 1982-11-01 | 1984-11-27 | Janssen Pharmaceutica N.V. | [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones |
| JP5858557B2 (en) | 2005-12-22 | 2016-02-10 | ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | TRPA1 inhibitor for treating pain |
| DE102006031314A1 (en) | 2006-07-01 | 2008-01-03 | Bayer Healthcare Aktiengesellschaft | Use of 1,4-diaryl-dihydropyrimidin-2-one derivative for producing a medicament for the treatment and/or prophylaxis of e.g. pulmonary arterial hypertension, chronic-obstructive lung diseases and sleep apnea syndrome |
| US20100010024A1 (en) | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
| US20110201634A1 (en) | 2008-06-13 | 2011-08-18 | Delhi University | Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same |
| WO2011115892A1 (en) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| JP5902029B2 (en) | 2011-04-28 | 2016-04-13 | 日本たばこ産業株式会社 | Amide compounds and their pharmaceutical uses |
| EP2682389A1 (en) | 2012-07-02 | 2014-01-08 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter |
| JO3215B1 (en) * | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | Carboxamide or Sulfonamide Substituted Nitrogen-Containing 5-Membered Heterocycles as Modulators for the Orphan Nuclear Receptor RORy |
| US10035790B2 (en) | 2012-10-19 | 2018-07-31 | Exelixis, Inc. | RORγ modulators |
| US20160137639A1 (en) | 2012-10-26 | 2016-05-19 | Japan Tobacco Inc. | Triazole-isoxazole compound and medical use thereof |
| CN103113308B (en) | 2013-01-25 | 2014-11-19 | 浙江大学 | A method for preparing dihydropyrimidinone derivatives |
| WO2015095795A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| TW201630881A (en) | 2014-12-12 | 2016-09-01 | Ｈ 朗德貝克公司 | A process for the manufacture of idalopirdine |
| AU2015360005A1 (en) | 2014-12-12 | 2017-07-27 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor |
| SI3231793T1 (en) * | 2014-12-12 | 2020-07-31 | Japan Tobacco Inc. | Dihydropyrimidine-2-one compounds and medicinal uses thereof |
| US9790180B2 (en) | 2014-12-12 | 2017-10-17 | Regenacy Pharmaceuticals, Llc | Piperidine derivatives as HDAC1/2 inhibitors |
| EP3405470B1 (en) * | 2016-01-20 | 2020-07-15 | Boehringer Ingelheim International GmbH | Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma |
-
2019
- 2019-02-27 MX MX2020008982A patent/MX2020008982A/en unknown
- 2019-02-27 US US16/287,870 patent/US10899717B2/en active Active
- 2019-02-27 WO PCT/JP2019/007433 patent/WO2019167981A1/en not_active Ceased
- 2019-02-27 JP JP2019033421A patent/JP7282546B2/en active Active
- 2019-02-27 AR ARP190100480A patent/AR114270A1/en not_active Application Discontinuation
- 2019-02-27 RU RU2020131402A patent/RU2020131402A/en unknown
- 2019-02-27 PE PE2020001289A patent/PE20210550A1/en unknown
- 2019-02-27 CA CA3087994A patent/CA3087994A1/en active Pending
- 2019-02-27 AU AU2019228915A patent/AU2019228915A1/en not_active Abandoned
- 2019-02-27 CN CN201980015795.4A patent/CN111741947B/en active Active
- 2019-02-27 TW TW108106799A patent/TW202000650A/en unknown
- 2019-02-27 BR BR112020016785-1A patent/BR112020016785A2/en not_active Application Discontinuation
- 2019-02-27 EP EP19759983.0A patent/EP3760616A4/en active Pending
- 2019-02-27 KR KR1020207024430A patent/KR20200126973A/en not_active Ceased
- 2019-02-27 SG SG11202007117RA patent/SG11202007117RA/en unknown
-
2020
- 2020-07-27 IL IL276323A patent/IL276323A/en unknown
- 2020-08-25 CL CL2020002187A patent/CL2020002187A1/en unknown
- 2020-08-27 PH PH12020551341A patent/PH12020551341A1/en unknown
- 2020-09-24 CO CONC2020/0011860A patent/CO2020011860A2/en unknown
- 2020-12-18 US US17/127,935 patent/US20210363110A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW202000650A (en) | 2020-01-01 |
| RU2020131402A (en) | 2022-03-24 |
| PH12020551341A1 (en) | 2021-06-21 |
| CN111741947A (en) | 2020-10-02 |
| AR114270A1 (en) | 2020-08-12 |
| AU2019228915A1 (en) | 2020-07-02 |
| JP7282546B2 (en) | 2023-05-29 |
| US10899717B2 (en) | 2021-01-26 |
| BR112020016785A2 (en) | 2021-02-09 |
| PE20210550A1 (en) | 2021-03-17 |
| IL276323A (en) | 2020-09-30 |
| US20190300488A1 (en) | 2019-10-03 |
| CL2020002187A1 (en) | 2020-12-18 |
| EP3760616A4 (en) | 2021-11-03 |
| MX2020008982A (en) | 2020-09-28 |
| KR20200126973A (en) | 2020-11-09 |
| CN111741947B (en) | 2024-06-11 |
| EP3760616A1 (en) | 2021-01-06 |
| JP2019151623A (en) | 2019-09-12 |
| CA3087994A1 (en) | 2019-09-06 |
| US20210363110A1 (en) | 2021-11-25 |
| CO2020011860A2 (en) | 2021-01-18 |
| WO2019167981A1 (en) | 2019-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2572126B (en) | Pharmaceutical | |
| GB2569961B (en) | Pharmaceutical | |
| GB2572125B (en) | Pharmaceutical | |
| IL277502A (en) | Compounds and uses thereof | |
| IL290745A (en) | Pyrimidine compound and pharmaceutical use thereof | |
| IL273339A (en) | Griseofulvin compound and pharmaceutical use thereof | |
| IL277749A (en) | Pladienolide compounds and their use | |
| GB201715194D0 (en) | Compounds and their therapeutic use | |
| IL276326A (en) | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | |
| GB201813312D0 (en) | Compounds and their therapeutic use | |
| IL276323A (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| IL278517A (en) | Azabenzimidazole compounds and pharmaceutical | |
| IL279483A (en) | Cyanotriazole compounds and uses thereof | |
| IL276311A (en) | Methyllactam ring compound and pharmaceutical use thereof | |
| IL280644A (en) | Magnesium-serinate compound and use thereof | |
| IL282134A (en) | Aromatic compounds and pharmaceutical uses thereof | |
| IL292646A (en) | Pharmaceutical combination and use thereof | |
| IL283540A (en) | Dock1-inhibiting compound and use thereof | |
| GB201814520D0 (en) | New pharmaceutical use | |
| GB201917327D0 (en) | New pharmaceutical use | |
| GB201913328D0 (en) | New Pharmaceutical use | |
| GB201802743D0 (en) | Medicament and use thereof | |
| GB201813311D0 (en) | Novel compounds and their use | |
| GB201702051D0 (en) | New Pharmaceutical use |